Impact of molecular residual disease post allografting in myelofibrosis patients
We screened 136 patients with myelofibrosis and a median age of 58 years who underwent allogeneic stem cell transplantation (AHSCT) for molecular residual disease for JAKV617F ( n =101), thrombopoietin receptor gene (MPL) ( n =4) or calreticulin (CALR) ( n =31) mutation in peripheral blood on day +1...
Gespeichert in:
Veröffentlicht in: | Bone marrow transplantation (Basingstoke) 2017-11, Vol.52 (11), p.1526-1529 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | We screened 136 patients with myelofibrosis and a median age of 58 years who underwent allogeneic stem cell transplantation (AHSCT) for molecular residual disease for JAKV617F (
n
=101), thrombopoietin receptor gene (MPL) (
n
=4) or calreticulin (CALR) (
n
=31) mutation in peripheral blood on day +100 and +180 after AHSCT. After a median follow-up of 78 months, the 5-year estimated overall survival was 60% (95% confidence interval (CI): 50–70%) and the cumulative incidence of relapse at 5 years was 26% (95% CI: 18–34%) for the entire study population. The percentage of molecular clearance on day 100 was higher in CALR-mutated patients (92%) in comparison with MPL- (75%) and JAKV617F-mutated patients (67%). Patients with detectable mutation at day +100 or at day +180 had a significant higher risk of clinical relapse at 5 years than molecular-negative patients (62% vs 10%,
P |
---|---|
ISSN: | 0268-3369 1476-5365 |
DOI: | 10.1038/bmt.2017.157 |